The present invention provides a class of novel compounds having Btk selective inhibitory activity, better metabolic stability and the like.

Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein.

A method of preparing a medicament for a treatment of anemia includes the step of using an antiplatelet thrombolysin in preparing the medicament, and the antiplatelet thrombolysin has an activity of improving the anemia. The antiplatelet thrombolysin consists of two peptide chains of α chain and β chain, in which the α chain amino acid sequence is shown in SEQ ID NO: 1, the β chain amino acid sequence is shown in SEQ ID NO: 2; or the antiplatelet thrombolysin is derived from the α chain amino acid sequence by substitution, deletion, or addition of one or more amino acids and has at least 95% identity with SEQ ID NO: 1; or the antiplatelet thrombolysin is derived from the β chain amino acid sequence by substitution, deletion, or addition of one or more amino acids and has at least 95% identity with SEQ ID NO: 2.

A method of preparing a medicament for a treatment of anemia includes the step of using an antiplatelet thrombolysin in preparing the medicament, and the antiplatelet thrombolysin has an activity of improving the anemia. The antiplatelet thrombolysin consists of two peptide chains of α chain and β chain, in which the α chain amino acid sequence is shown in SEQ ID NO: 1, the β chain amino acid sequence is shown in SEQ ID NO: 2; or the antiplatelet thrombolysin is derived from the α chain amino acid sequence by substitution, deletion, or addition of one or more amino acids and has at least 95% identity with SEQ ID NO: 1; or the antiplatelet thrombolysin is derived from the β chain amino acid sequence by substitution, deletion, or addition of one or more amino acids and has at least 95% identity with SEQ ID NO: 2.

The present disclosure relates to aqueous compositions for anti-IL17a antibodies, and more particularly to aqueous compositions for anti-IL17a antibodies with a V.sub.HH variable domain and a V.sub.L variable domain, and can be used as a medicinal agent for treating IL-17A-mediated diseases.

Aspects of the application provide hepcidin antagonists and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis. In certain embodiments, methods are provided for treating myelofibrosis, which is generally characterized as a myeloproliferative disease associated with chronic inflammation and progressive marrow fibrosis. Anemia is a major clinical problem in myelofibrosis and is associated with negative outcomes. Such anemia is generally caused by, or associated with, bone marrow failure, splenomegaly and/or functional iron deficiency, which may contribute to inflammation.

Aspects of the application provide hepcidin antagonists and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis. In certain embodiments, methods are provided for treating myelofibrosis, which is generally characterized as a myeloproliferative disease associated with chronic inflammation and progressive marrow fibrosis. Anemia is a major clinical problem in myelofibrosis and is associated with negative outcomes. Such anemia is generally caused by, or associated with, bone marrow failure, splenomegaly and/or functional iron deficiency, which may contribute to inflammation.

Aspects of the application provide hepcidin antagonists and methods of using the same in treating anemias of chronic disease, iron-restricted anemias, and/or conditions associated with anemia. Accordingly, aspects of the present disclosure relate to treating a subject with high hepcidin levels (e.g., ACD) by inhibiting the BMP signaling pathway (e.g., hemojuvelin-induced BMP signaling pathway) and/or the inflammatory response (e.g., IL-6 mediated inflammatory pathway).

Aspects of the application provide hepcidin antagonists and methods of using the same in treating anemias of chronic disease, iron-restricted anemias, and/or conditions associated with anemia. Accordingly, aspects of the present disclosure relate to treating a subject with high hepcidin levels (e.g., ACD) by inhibiting the BMP signaling pathway (e.g., hemojuvelin-induced BMP signaling pathway) and/or the inflammatory response (e.g., IL-6 mediated inflammatory pathway).

[Problem] To provide a composition or the like that suppresses the physical destruction of red blood cells (hemolysis) due to exercises and behaviors associated with impact such as striking, for example, as when continually hitting the soles of the feet on the ground by continued running, by using astaxanthin which has a long history of use as a food, and to provide a composition or the like for making the number of red blood cells destroyed (hemolysis number) to lower than the number of red blood cells newly created by hematopoiesis (hematopoiesis number), to suppress and/or improve exercise-induced hemolytic anemia caused by the physical destruction of red blood cells (hemolysis).

[Solution] Astaxanthin is used as an active ingredient.